Avidity Biosciences' CEO Sarah Boyce discusses the company's Exon 44 skipping data in DMD that showed a 25% increase in dystrophin production
Dr. Maha Radhakrishnan, former Biogen CMO, joined Sofinnova Investments this week as Executive Partner
Scholar Rock's CEO on a big phase 3 readout coming later this year in SMA, myostatin inhibition for obesity, and more
Nello Mainolfi shares an update on Kymera and the progress of the protein degradation field
Oppenheimer analyst Jay Olson joins BiotechTV for Analyst Thursdays and talks obesity and earnings
Servier's U.S. CEO discusses FDA approval of Voranigo, a targeted therapy for a common type of brain cancer
The CEO of UK based Levicept shares background on the company's neurotrophin-3 inhibiting fusion protein, which they say succeeded today in pain management in an osteoarthritis phase 2 study
Stoke Therapeutics' CEO Ed Kaye on using RNA medicines to upregulate protein expression, and the company's progress in Dravet Syndrome
Adaptimmune's CEO discusses last night's FDA accelerated approval of TECELRA, a TCR-based engineered cell therapy for synovial sarcoma
Jefferies' SVP Andrew Tsai joins BiotechTV for Analyst Thursdays and talks neuro names and more
Cambridge, UK based Healx, an AI powered rare disease company, announced a $47M series C financing today
io9 published data in the Journal of Clinical Oncology today demonstrating that its AI biomarker platform OncoGaze identified HRD-positive patients from routine tissue slides
Autobahn Therapeutics announced a $100M series C this week as it prepares to move its thyromimetic into phase 2 for MDD and bipolar disorder depression
AI x Bio Summit: Bessemer Venture Partners' Morgan Cheatham shares his take on AI in life sciences
AI x Bio Summit: The Co-Founder of Kernal Bio describes designing mRNA therapies that are selectively delivered to, and translated by, specific cells in the body
AI x Bio Summit: Generate Biomedicines' CEO Mike Nally gives an update on the company's clinical and emerging programs
AI x Bio Summit: Co-Founder Transon Nguyen describes how AI is enabling Eigen Therapeutics to become a discovery engine for priming therapies
The Co-Hosts of the AI x Bio Summit at NYSE talk about the conference and their take on AI
Philadelphia area based XyloCor is developing a gene therapy with the goal of helping to revascularize the heart for refractory angina patients
Visiting the Stevenage Bioscience Catalyst, a key life sciences research campus in the UK
.png){kind=logo}
